Aldeyra Therapeutics,
Inc. ALDX (Aldeyra), a biotechnology company focused on the
development of products to treat diseases related to free aldehydes, today
announced the expansion of its drug development team with three strategic
hires to support upcoming studies for its lead product candidate, NS2.
Donna Keith will supervise Chemistry Manufacturing and Controls (CMC), while
Dr. Philip L. Piscitelli and Rachel G. Sorensen will supervise clinical
development. Collectively, the team has over 40 years of drug development
experience with companies such as Genzyme, Vertex Pharmaceuticals, Baxter
International, MGI Pharma, Synageva BioPharma, and Verastem.
"We are pleased to announce the recruitment of a highly experienced and
accomplished group of pharmaceutical professionals to Aldeyra. With these key
hires, we are well-positioned to continue the development of NS2 for its two
lead indications," said Scott L. Young, Chief Operating Officer of Aldeyra
Therapeutics. "We look forward to the contributions from our team as we work
to develop novel therapies for the treatment of serious diseases that are
related to free aldehyde toxicity."
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in